---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Cost-effectiveness evidence"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Cost-effectiveness evidence. Topics: Summary: acquisition prices of on-demand agents by price type; Summary: cost per attack, redosing, and cost of illness; Summary: published cost-effectiveness analyses of on-demand agents and their inputs; Summary: utility weights for attack and attack-free states; 51 further topics. 55 evidence topics quoted from 38 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics/cost-effectiveness"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary: acquisition prices of on-demand agents by price type

- Wholesale acquisition cost (WAC), oral sebetralstat (Ekterly) 300 mg: $33,440.0000 at introduction on 2025-07-07 for a pack of 4 tablets (California filing); $8,360 per tablet, $16,720 per dose of two tablets, and $33,440 per package of two doses (Missouri Medicaid fact blast, 2025); $35,614 per carton of 4 tablets (KalVista Colorado disclosure, 2026); and $35,614.0000 at introduction on 2026-09-21 for a 4-tablet pack (California filing, 2026).
- WAC, Berinert 500 units (NDC 63833082502): $3,250.00 effective 01/01/2021, $3,415.75 on 01/01/2022, $3,620.69 on 01/01/2023, $3,837.93 on 01/01/2024, $4,068.20 on 07/01/2024, $4,271.61 on 01/01/2025, and $4,442.47 on 01/01/2026.
- WAC, Ruconest 2100 U, 1 carton: $7,625.00 effective 01/01/2024 and $8,075.00 effective 01/01/2025.
- WAC at introduction, generic icatibant and Sajazir: $5,083.26 per single syringe and $15,249.78 per 3 (Teva, 2019-07-15); $5,083.26 per single unit (Cipla, 2020-07-20; Fresenius Kabi, 2020-10-21); $2,795.79 (Apotex, 2021-04-15); $5,000.00 per vial and $15,000.00 per 3 vials (Sajazir, 2021-08-16); $1,000.00 per syringe and $3,000.00 per 3 (AuroMedics, 2025-05-20); $750.00 per vial and $2,250.00 per 3 vials (Alembic, 2025-09-25). The Sajazir manufacturer states that the WAC for Firazyr was $11,147.49 (NDC 54092-0702-02) and that parity with Firazyr was one determining factor of its price; a 2025 generic entrant states that it is launching its product as a lower price generic product.
- Federal Supply Schedule (FSS) and Big Four prices, 2026 VA file: Firazyr 30 mg/3 mL $9,522.98 FSS and $7,284.86 Big Four per syringe, $28,568.96 FSS and $20,309.55 Big Four per 3; generic icatibant $979.90 and $2,939.70 FSS (Fresenius Kabi, 3 mL and 3 x 3 mL) and $2,317.97 and $6,952.90 FSS (NDCs 00093-3066-34 and 00093-3066-93); Kalbitor 10 mg/mL, 3 x 1 mL, $16,754.10 FSS and $12,431.63 Big Four; Berinert 500 IU vial $3,217.25 FSS and $2,650.06 Big Four; Ruconest 2100 unit vial $4,918.75 FSS and Big Four.
- Medicare Part B payment limits, October 1 to December 31, 2026, based on 2Q26 ASP data: Berinert (J0597) $79.329 per 10 units with a co-insurance percentage of 18.454; Ruconest (J0596) $37.810 per 10 units and Kalbitor (J1290) $599.616 per 1 mg, each with 20.000.
- Medicare Part D, 2024: average spending per beneficiary was $257140.16824 for Firazyr (170 beneficiaries), $49357.793951 for generic icatibant (658), $549167.57048 for Berinert (63), $435241.23625 for Ruconest (128), and $579766.23194 for Kalbitor (36).
- Prices outside the United States, sebetralstat: £12,000 list price for a 300-mg pack of 6 tablets, including VAT, in the English company submission; €17,707.74 pharmacy sales price and €16,697.97 after statutory rebates for 6 film-coated tablets in Germany.
- Historical per-dose inputs (ICER, 2018): FSS or Big Four price as of September 15, 2018 of $4,174 (Berinert, 20 IU/kg), $11,174 (Kalbitor, 30 mg), $7,178 (Firazyr, 30 mg), and $10,112 (Ruconest, 50 IU/kg); average sales price as of June 13, 2018 plus a 9% markup of $9,807, $15,594, $7,178, and $15,164.

Source: [California HCAI prescription drugs introduced to market (2025)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/80eea566-e1a0-4b62-884b-b0dfb58887e3/download/q1-q4-2025-prescription-drugs-introduced-to-market.xlsx); [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx); [KalVista Pharmaceuticals Colorado WAC disclosure (2026)](https://www.kalvista.com/wp-content/uploads/2026/05/Colorado-WAC-Disclosure-Ekterly-updated-20260504.pdf); [California HCAI prescription drugs introduced to market (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv); [California HCAI five-year WAC increase history (2026)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/d754c567-c3c3-4ecf-a236-8144578549dd/download/5-year-wac-increase-history-jan-oct-2026.csv); [California HCAI WAC increase data (2024)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/882bb30d-44ed-48c9-b722-beb5aedc2c1b/download/q1-q4-2024-prescription-drug-wac-increases.xlsx); [California HCAI WAC increase data (2025)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/46b78eef-5952-4fff-84c7-1fa758990ce8/download/q1-q4-2025-prescription-drug-wac-increases.xlsx); [California HCAI prescription drugs introduced to market (2019)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/6393cda0-6101-424e-b738-07aee9e6f94f/download/q1-q4-2019-prescription-drugs-introduced-to-market.xlsx); [California HCAI prescription drugs introduced to market (2020)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/9a37709e-4151-4300-a031-91ea7813da60/download/q1-q4-2020-prescription-drugs-introduced-to-market.xlsx); [California HCAI prescription drugs introduced to market (2021)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/5a80b890-24bb-4d66-a0bb-d6c46a150065/download/q1-q4-2021-prescription-drugs-introduced-to-market.xlsx); [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://department.va.gov/procurement-acquisition-and-logistics/wp-content/uploads/sites/56/2026/11/TPharmPrices-11-01-2026.xlsx); [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip); [CMS Medicare Part D Spending by Drug (2026)](https://data.cms.gov/sites/default/files/2026-06/98218f98-166c-4723-8438-c344a4ef96a6/DSD_PTD_RY26_P04_V10_DY24_BGM.csv); [NICE sebetralstat draft guidance (2025)](https://www.nice.org.uk/guidance/gid-ta11334/documents/draft-guidance); [G-BA sebetralstat resolution justification (2026)](https://www.g-ba.de/downloads/40-1465-12519/2026-04-02_AM-RL-XII_Sebetralstat_D-1248_TrG_EN.pdf); [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-2"></a>

### Summary: cost per attack, redosing, and cost of illness

- Cost per attack: the 2018 ICER report states that on-demand medications range in cost from $5,000 to more than $12,000 per attack treated in the US. In an Italian cohort analyzed from the Italian National Health Service perspective, 1190 of the attacks (78.9%) were treated on demand, 704 with pdC1-INH and 486 with icatibant; the average cost per attack was €1183 (SD €789), the unadjusted mean was €1069 (SD €470) with pdC1-INH and €1651 (SD €469) with icatibant, and after controlling for attack site and severity the icatibant cost remained 54% higher.
- Redosing: the Missouri Medicaid fact blast reports redosing in 13% to 38% of episodes with sebetralstat, 7% to 44% with icatibant, 8% to 30% with Berinert, 6% to 18% with Kalbitor, and 2% to 10% with Ruconest. The ICER model used extra-dose percentages of 1.9% (Berinert), 12.0% (Kalbitor), 12.7% (Firazyr), and 6.6% (Ruconest), and assumed equal proportions of attacks treated with each drug in each setting.
- Acute care unit costs in the ICER model: home nurse $177, physician office administration $262, ED visit $1,479 (95% CI: $1,028-$1,929), and hospitalization $4,760 (95% CI: $3,612-$5,907); indirect costs per attack of $959 for mild, $4,048 for moderate, and $6,656 for severe attacks.
- Annual costs: modeled on-demand-only treatment in a patient survey carried direct costs of $363,795 and indirect costs of $52,576 per patient per year, with medications at $227,674 (62.5%), hospitalization at 22.1%, and ED visits at 12.5%. In claims data, per patient per year costs before and after starting long-term prophylaxis were $165,348 and $515,333 in total, with on-demand pharmacy costs of $217,857 and $167,462 and long-term prophylaxis pharmacy costs of $0 and $395,845 among patients with at least 1 claim; 67% had at least 1 post-index on-demand therapy claim.
- Self-administration: a Spanish one-year cost-minimization model estimated average savings of €121.30 per acute attack from the social perspective for its strategy 2, and annual savings of €551,371 for Spain.

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf); [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/); [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx); [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/); [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/); [Blasco et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3584739/)

<a id="topic-4.1-3"></a>

### Summary: published cost-effectiveness analyses of on-demand agents and their inputs

- A US commercial payer decision-tree model (costs dated to 2019) of ecallantide, icatibant, pdC1-INH, and rhC1-INH estimated costs and effectiveness per attack of $12,905 and 0.806 for rhC1-INH, $14,806 and 0.765 for icatibant, $14,668 and 0.769 for pdC1-INH, and $21,068 and 0.792 for ecallantide. Using 26.9 attacks per person-year, cost per QALY was $420,941, $488,349, $483,892, and $689,773, respectively, and the authors report rhC1-INH as the dominant option.
- A Polish one-year discrete event simulation from the healthcare payer's perspective compared conestat alfa and plasma-derived C1 inhibitor with placebo: QALY gains of 0.0261 and 0.0262, incremental costs of approximately EUR 419 for a single attack treated with conestat alfa and approximately EUR 755 per patient for human C1-INH, and median incremental cost-utility ratios of EUR 15,226 and EUR 27,786 per QALY against a threshold of EUR 24,279 (PLN 99,543) per QALY.
- The 2018 ICER prophylaxis model assumed on-demand treatment for acute attacks in the comparator arm and computed average costs per attack weighted by the proportion of attacks treated with each drug in each setting.
- No published cost-effectiveness analysis of deucrictibant was identified.

Source: [Bernstein et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391298/); [Kawalec et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3834719/); [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-4"></a>

### Summary: utility weights for attack and attack-free states

- US on-demand decision model: 0.51 when experiencing attack symptoms and 0.83 without symptoms.
- ICER 2018 model: attack-free EQ-5D utility of 0.825 ± 0.207, with disutilities of 0.070, 0.369, and 0.486 for mild, moderate, and severe attacks.
- European survey mapped to UK EQ-5D weights (111 participants): 0.44 during an attack and 0.72 between attacks; 0.61, 0.47, and 0.08 for no or mild, moderate, and severe pain during the last attack.
- US survey (KalVista-funded): EQ-5D-5L index of 0.849 today and 0.568 during the last treated attack in the treated cohort, 0.667 when treated within 1 hour of onset and 0.504 when treated 5 to less than 8 hours after onset, and 0.859 today and 0.661 during the last untreated attack in the untreated cohort.
- Time trade-off with the general public in England (BioCryst-funded): attack-free 0.783, hand 0.582, facial 0.483, abdominal 0.345, laryngeal 0.128, and caregiver 0.762.
- A US qualitative study of 25 adults with HAE concluded that severity definitions for evaluating new treatments should incorporate attack location, symptoms, and phase.

Source: [Bernstein et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391298/); [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf); [Aygören-Pürsün et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5019462/); [O'Connor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12320545/); [Lo et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8864034/); [Gallop et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2740956)

<a id="topic-4.1-5"></a>

### Summary: health technology assessments of oral on-demand sebetralstat

- England: the NICE draft guidance states that sebetralstat should not be used to treat HAE attacks in people 12 years and over and that the most likely cost-effectiveness estimates cannot be determined. The company base-case ICER against a basket of treatments was “considerably higher than £30,000 per QALY gained”; exact ICERs are confidential. KONFIDENT did not collect health-related quality of life data, utilities were informed by the Lo et al. (2022) time trade-off analysis, and the company base case applied no disutility difference between subcutaneous and oral administration. The 2026 project page states that NICE paused publication of the draft guidance due to exceptional circumstances, that an updated commercial offer has been agreed, that publication of the final draft guidance is paused until mid-November, and that sebetralstat remains available through the EAMS plus route.
- Germany: the G-BA found a “hint for a non-quantifiable additional benefit”, noted that no health-related quality of life data were collected, and costed 1 or 2 doses per attack at one attack every three weeks to one attack every week.
- France: the HAS transparency committee, on 22 April 2026, rated the medical benefit (SMR) of Ekterly as important and its added benefit as ASMR V, and estimated about 1 850 patients with HAE in France and a target population of 1 600.

Source: [NICE sebetralstat draft guidance (2025)](https://www.nice.org.uk/guidance/gid-ta11334/documents/draft-guidance); [NICE sebetralstat project page (2026)](https://www.nice.org.uk/guidance/indevelopment/gid-ta11334); [G-BA sebetralstat resolution justification (2026)](https://www.g-ba.de/downloads/40-1465-12519/2026-04-02_AM-RL-XII_Sebetralstat_D-1248_TrG_EN.pdf); [HAS EKTERLY transparency committee opinion (2026)](https://www.has-sante.fr/upload/docs/evamed/CT-21620_EKTERLY_PIC_INS_AvisDef_CT21620.pdf)

<a id="topic-4.1-6"></a>

### Summary: payer utilization management of on-demand agents

- Cigna (review date 07/08/2026): Ekterly quantity limits sufficient to treat 4 attacks at the maximum dose per 28 days, assuming two 600 mg doses in 24 hours per attack, with an override for an additional 4 attacks each month.
- Univera Healthcare: for patients 18 years and older, Ekterly requires documentation of therapeutic failure, severe intolerance, or a contraindication to generic icatibant, with a quantity limit of 4 tablets per 30 days; brand Firazyr requires the same documentation regarding generic icatibant; quantity limits of 3 pre-filled syringes (9 mL) per 30 days and 10 vials per 30 days on the prescription benefit appear in the policy; one acute HAE medication is authorized at one time.
- Regence (effective April 1, 2026): documentation that generic icatibant and at least one of Berinert or Ruconest have been ineffective, not tolerated, or contraindicated; acute treatments authorized in a quantity sufficient for three attacks per month; generic icatibant described as the lowest cost of all available options.
- CountyCare medical benefit: lists Berinert (J0597), Firazyr (J1744), Kalbitor (J1290), and Ruconest (J0596), and requires trial and failure or intolerance of the preferred product for non-preferred requests.
- MO HealthNet: Ekterly prior authorization for on-demand treatment of acute HAE attacks with an initial approval period of 6 months; the fact blast lists deucrictibant with a phase III trial (NCT06669754) and an estimated completion of August 2026; the sponsor identifies NCT06669754 as CHAPTER-3, its trial of deucrictibant XR for prophylaxis.

Source: [Cigna Ekterly drug quantity management policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_934_coveragepositioncriteria_hae_ekterly_dqm_per_days.pdf); [Univera Healthcare hereditary angioedema pharmacy policy (2026)](https://www.univerahealthcare.com/documents/d/global/hereditary-angioedema-hae-pdf); [Regence medication policy dru535 (2026)](https://regence.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/Cambia/Program_Summaries/dru535reg.pdf); [CountyCare acute HAE products guideline (2026)](https://countycare.com/wp-content/uploads/ECG_5000.CC-for-Acute-Hereditary-Angioedema-Products-ver-Jan-26.pdf); [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx); [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-4.1-7"></a>

### Summary: population, market size, and company statements

- US population: claims-based estimates of 9559, 9341, and 8694 people diagnosed with HAE in 2018, 2019, and 2020, and expert physician estimates of 7602, 7275, and 6595 (Castaldo et al. (2025)); fewer than 8000 people in the United States with HAE due to C1 inhibitor deficiency (Castaldo et al. (2021)); and, as a company statement citing HAE International as of October 2014, at least 7,000 patients in the U.S. and at least 15,000 in the EU (Pharvaris 20-F).
- Treatment pattern: 37.3% (n = 275) of 737 survey respondents used on-demand-only treatment; approximately 70% of US patients with HAE are treated with long-term prophylaxis (Tachdjian et al. (2026)).
- Payer mix: The California filing for sebetralstat states a payer mix of 70% commercial payors, 25% Medicare Part D, and 5% Medicaid, with estimated patient numbers of 780 (2025 filing) and 7500 (2026 filing).
- Market size: Pharvaris states that global sales of HAE treatments in 2024 were estimated at approximately $2.7 billion and, according to public research reports, are forecast to reach $4.7 billion through 2036; an ADARx prospectus cites approximately $3.12 billion in 2024 and approximately $6.83 billion by 2032 (Evaluate Pharma).
- Company statements: Pharvaris states a median of 14 attacks per year according to scientific publications, expects its product candidates, if approved, to be priced at a “significant premium over competitive generic products”, and expects generic products to create potential pricing pressure. Its third quarter 2026 discussion attributes expenses to pricing research and HAE market data supporting a potential launch of IR in 2027, and expects revenues from sales in 2027 if deucrictibant IR is approved by the FDA.

Source: [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/); [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/); [California HCAI prescription drugs introduced to market (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv); [California HCAI prescription drugs introduced to market (2025)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/80eea566-e1a0-4b62-884b-b0dfb58887e3/download/q1-q4-2025-prescription-drugs-introduced-to-market.xlsx); [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm); [Pharvaris Form 6-K, third quarter 2026 MD&A (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm)

<a id="topic-4.1-8"></a>

### Wholesale acquisition cost of oral on-demand sebetralstat at introduction, July 2025

| Product | NDC | Date introduced to market | WAC at introduction ($) | Estimated number of patients |
| --- | --- | --- | --- | --- |
| “Ekterly Oral Tablet 300 MG (4 EA)” | “82928030004” | “2025-07-07” | “33440.0000” | “780” |

Source: [California HCAI prescription drugs introduced to market (2025)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/80eea566-e1a0-4b62-884b-b0dfb58887e3/download/q1-q4-2025-prescription-drugs-introduced-to-market.xlsx)

> “Price Per Unit (WAC)”
> “WAC: $8,360 per tablet; $16,720 per dose (two 300-mg tablets).”
> “Each pack contains two doses (4 tablets); total WAC of $33,440 per package”

Source: [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx)

<a id="topic-4.1-9"></a>

### Wholesale acquisition cost of oral on-demand sebetralstat, 2026

> “Ekterly® (sebetralstat) 300mg tablet $35,614 per 4 tablets carton”

Source: [KalVista Pharmaceuticals Colorado WAC disclosure (2026)](https://www.kalvista.com/wp-content/uploads/2026/05/Colorado-WAC-Disclosure-Ekterly-updated-20260504.pdf)

| Product | NDC | Date introduced to market | WAC at introduction ($) | Estimated number of patients |
| --- | --- | --- | --- | --- |
| “Ekterly tablet 300mg, 4” | “82928030005” | “2026-09-21” | “35614.0000” | “7500” |

Source: [California HCAI prescription drugs introduced to market (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv)

<a id="topic-4.1-10"></a>

### Manufacturer's stated payer mix for the sebetralstat launch, California filing

> “The marketing investments are organized to reflect a payer mix of 70% commercial payors, 25% Medicare Part D, and 5% Medicaid, ensuring targeted activity and access initiatives across these payer ecosystems.”

Source: [California HCAI prescription drugs introduced to market (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv)

<a id="topic-4.1-11"></a>

### Wholesale acquisition cost of Berinert, 2021 to 2026

| Product | NDC | WAC effective date | WAC increase amount ($) | WAC after increase ($) |
| --- | --- | --- | --- | --- |
| “Berinert 500 units (500 IU / Solution / Pkg Size 1)” | “63833082502” | “01/01/2026” | “170.86” | “4442.47” |

Source: [California HCAI WAC increase data (2026)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/dda8a083-bc81-4f6d-b02f-935a2df70328/download/wac-increase-data-jan-oct-2026.csv)

| NDC | WAC effective date | WAC increase amount | WAC amount |
| --- | --- | --- | --- |
| “63833082502” | “01/01/2021” | “$150.00” | “$3,250.00” |
| “63833082502” | “01/01/2022” | “$165.75” | “$3,415.75” |
| “63833082502” | “01/01/2023” | “$204.94” | “$3,620.69” |
| “63833082502” | “01/01/2024” | “$217.24” | “$3,837.93” |
| “63833082502” | “07/01/2024” | “$230.27” | “$4,068.20” |
| “63833082502” | “01/01/2025” | “$203.41” | “$4,271.61” |
| “63833082502” | “01/01/2026” | “$170.86” | “$4,442.47” |

Source: [California HCAI five-year WAC increase history (2026)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/d754c567-c3c3-4ecf-a236-8144578549dd/download/5-year-wac-increase-history-jan-oct-2026.csv)

<a id="topic-4.1-12"></a>

### Wholesale acquisition cost of Ruconest, 2024 and 2025

| Product | NDC | WAC effective date | WAC increase amount ($) | WAC after increase ($) |
| --- | --- | --- | --- | --- |
| “Ruconest 2100 U; Injection; Powder for Solution; 1 Carton” | “71274035002” | “01/01/2024” | “355.00” | “7625.00” |

Source: [California HCAI WAC increase data (2024)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/882bb30d-44ed-48c9-b722-beb5aedc2c1b/download/q1-q4-2024-prescription-drug-wac-increases.xlsx)

| Product | NDC | WAC effective date | WAC increase amount ($) | WAC after increase ($) |
| --- | --- | --- | --- | --- |
| “Ruconest 2100 U; Injection; Powder for Solution; 1 Carton” | “71274035002” | “01/01/2025” | “450.00” | “8075.00” |

Source: [California HCAI WAC increase data (2025)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/46b78eef-5952-4fff-84c7-1fa758990ce8/download/q1-q4-2025-prescription-drug-wac-increases.xlsx)

<a id="topic-4.1-13"></a>

### Wholesale acquisition cost of generic icatibant and Sajazir at introduction, 2019 to 2025

| Manufacturer | Product | NDC | Date introduced to market | WAC at introduction ($) |
| --- | --- | --- | --- | --- |
| “Teva Pharmaceuticals USA” | “ICATIBANT ACETATE 10MG/ML PFS SOL 3ML 1” | “00093306634” | “2019-07-15” | “5083.2600” |
| “Teva Pharmaceuticals USA” | “ICATIBANT ACETATE 10MG/ML PFS SOL 3ML 3” | “00093306693” | “2019-07-15” | “15249.7800” |

Source: [California HCAI prescription drugs introduced to market (2019)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/6393cda0-6101-424e-b738-07aee9e6f94f/download/q1-q4-2019-prescription-drugs-introduced-to-market.xlsx)

| Manufacturer | Product | NDC | Date introduced to market | WAC at introduction ($) |
| --- | --- | --- | --- | --- |
| “Cipla USA, Inc.” | “Icatibant Acetate Subcutaneous Solution 30 MG/3ML” | “69097066434” | “2020-07-20” | “5083.2600” |
| “Fresenius Kabi USA LLC” | “Icatibant Injection 30 mg per 3 mL pack of 1” | “63323057486” | “2020-10-21” | “5083.2600” |

Source: [California HCAI prescription drugs introduced to market (2020)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/9a37709e-4151-4300-a031-91ea7813da60/download/q1-q4-2020-prescription-drugs-introduced-to-market.xlsx)

| Manufacturer | Product | NDC | Date introduced to market | WAC at introduction ($) |
| --- | --- | --- | --- | --- |
| “Apotex Corp” | “Icatibant Acetate Inj” | “60505621401” | “2021-04-15” | “2795.7900” |
| “Cycle Pharmaceuticals Limited” | “Sajazir (icatibant) 30mg/3ml vial, 1 vial package” | “70709001301” | “2021-08-16” | “5000.0000” |
| “Cycle Pharmaceuticals Limited” | “Sajazir (icatibant) 30mg/3ml vial, 3 vials/package” | “70709001303” | “2021-08-16” | “15000.0000” |

Source: [California HCAI prescription drugs introduced to market (2021)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/5a80b890-24bb-4d66-a0bb-d6c46a150065/download/q1-q4-2021-prescription-drugs-introduced-to-market.xlsx)

| Manufacturer | Product | NDC | Date introduced to market | WAC at introduction ($) |
| --- | --- | --- | --- | --- |
| “AuroMedics Pharma LLC” | “Icatibant Injection, SD PFS 30mg/3mL - 1s” | “55150035101” | “2025-05-20” | “1000.0000” |
| “AuroMedics Pharma LLC” | “Icatibant Injection, SD PFS 30mg/3mL - 3s” | “55150035103” | “2025-05-20” | “3000.0000” |
| “Alembic Pharmaceuticals, Inc.” | “Icatibant Injection, 1 x 3mL Single Dose Vial” | “62332065403” | “2025-09-25” | “750.0000” |
| “Alembic Pharmaceuticals, Inc.” | “Icatibant Injection, 3 x 3mL Single Dose Vial” | “62332065409” | “2025-09-25” | “2250.0000” |

Source: [California HCAI prescription drugs introduced to market (2025)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/80eea566-e1a0-4b62-884b-b0dfb58887e3/download/q1-q4-2025-prescription-drugs-introduced-to-market.xlsx)

<a id="topic-4.1-14"></a>

### Wholesale acquisition cost of Firazyr at the 2021 introduction of Sajazir, as stated by the Sajazir manufacturer

> “One of the determining factors was review of and parity with the analog drug Firazyr 2mg which is manufactured by Takeda Pharmaceuticals America Inc.”
> “Information available at the time indicates the WAC for Firazyr was $11,147.49 and NDC 54092-0702-02.”

Source: [California HCAI prescription drugs introduced to market (2021)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/5a80b890-24bb-4d66-a0bb-d6c46a150065/download/q1-q4-2021-prescription-drugs-introduced-to-market.xlsx)

<a id="topic-4.1-15"></a>

### Pricing plan stated for a generic icatibant introduced in 2025

> “We are launching the product as a lower price generic product with minimal marketing.”

Source: [California HCAI prescription drugs introduced to market (2025)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/80eea566-e1a0-4b62-884b-b0dfb58887e3/download/q1-q4-2025-prescription-drugs-introduced-to-market.xlsx)

<a id="topic-4.1-16"></a>

### Federal Supply Schedule and Big Four prices of on-demand agents, November 2026

| Product | Package | NDC | Package size | Price type | Price ($) |
| --- | --- | --- | --- | --- | --- |
| Icatibant (Firazyr) | “FIRAZYR 30MG/3ML INJECTION” | “54092-0702-02” | “1” | “Big4” | “7284.86” |
| Icatibant (Firazyr) | “FIRAZYR 30MG/3ML INJECTION” | “54092-0702-02” | “1” | “FSS” | “9522.98” |
| Icatibant (Firazyr) | “FIRAZYR 30MG/3ML INJECTION” | “54092-0702-03” | “3” | “Big4” | “20309.55” |
| Icatibant (Firazyr) | “FIRAZYR 30MG/3ML INJECTION” | “54092-0702-03” | “3” | “FSS” | “28568.96” |
| Icatibant (generic, Fresenius Kabi) | “ICATIBANT 10MG/ML (PF) INJ,SYRINGE,3ML” | “63323-0574-86” | “3ML” | “FSS” | “979.90” |
| Icatibant (generic, Fresenius Kabi) | “ICATIBANT 10MG/ML (PF) INJ,SYRINGE,3ML” | “63323-0574-93” | “3X3ML” | “FSS” | “2939.70” |
| Icatibant (generic, AvKare) | “ICATIBANT 10MG/ML (PF) INJ,SYRINGE,3ML” | “00093-3066-34” | “3ML” | “FSS” | “2317.97” |
| Icatibant (generic, AvKare) | “ICATIBANT 10MG/ML (PF) INJ,SYRINGE,3ML” | “00093-3066-93” | “3X3ML” | “FSS” | “6952.90” |
| Ecallantide (Kalbitor) | “KALBITOR 10MG/ML INJ” | “47783-0101-01” | “3X1ML” | “Big4” | “12431.63” |
| Ecallantide (Kalbitor) | “KALBITOR 10MG/ML INJ” | “47783-0101-01” | “3X1ML” | “FSS” | “16754.10” |
| C1 esterase inhibitor, plasma-derived (Berinert) | “BERINERT C1 INHIBITOR 500 IU/VIL” | “63833-0825-02” | “1” | “Big4” | “2650.06” |
| C1 esterase inhibitor, plasma-derived (Berinert) | “BERINERT C1 INHIBITOR 500 IU/VIL” | “63833-0825-02” | “1” | “FSS” | “3217.25” |
| C1 esterase inhibitor, recombinant (Ruconest) | “RUCONEST 2100UNITS/VIL INJ,PWDR” | “71274-0350-02” | “1” | “Big4” | “4918.75” |
| C1 esterase inhibitor, recombinant (Ruconest) | “RUCONEST 2100UNITS/VIL INJ,PWDR” | “71274-0350-02” | “1” | “FSS” | “4918.75” |

Source: [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://department.va.gov/procurement-acquisition-and-logistics/wp-content/uploads/sites/56/2026/11/TPharmPrices-11-01-2026.xlsx)

<a id="topic-4.1-17"></a>

### Medicare Part B payment limits for physician-administered on-demand agents, fourth quarter of 2026

> “Effective October 1, 2026 through December 31, 2026”
> “Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data.”

Source: [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

| Product | HCPCS code | Short description | Dosage unit | Payment limit ($) | Co-insurance percentage |
| --- | --- | --- | --- | --- | --- |
| C1 esterase inhibitor, on-demand (Berinert) | “J0597” | “C-1 esterase, berinert” | “10 UNITS” | “79.329” | “18.454” |
| Recombinant C1 esterase inhibitor, on-demand (Ruconest) | “J0596” | “Injection, ruconest” | “10 UNITS” | “37.810” | “20.000” |
| Ecallantide, on-demand (Kalbitor) | “J1290” | “Ecallantide injection” | “1 MG” | “599.616” | “20.000” |

Source: [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

> “Inflation-adjusted coinsurance”

Source: [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

<a id="topic-4.1-18"></a>

### Medicare Part D spending on on-demand agents, 2024

| Brand | Total spending, 2024 ($) | Beneficiaries, 2024 | Average spending per dosage unit, 2024 ($) | Average spending per beneficiary, 2024 ($) |
| --- | --- | --- | --- | --- |
| Firazyr (icatibant) | “43713828.6” | “170” | “3553.9698049” | “257140.16824” |
| Icatibant (generic) | “32477428.42” | “658” | “955.46002803” | “49357.793951” |
| Berinert (C1 esterase inhibitor) | “34597556.94” | “63” | “3904.4754475” | “549167.57048” |
| Ruconest (recombinant C1 esterase inhibitor) | “55710878.24” | “128” | “7557.0914596” | “435241.23625” |
| Kalbitor (ecallantide) | “20871584.35” | “36” | “5624.2480059” | “579766.23194” |

Source: [CMS Medicare Part D Spending by Drug (2026)](https://data.cms.gov/sites/default/files/2026-06/98218f98-166c-4723-8438-c344a4ef96a6/DSD_PTD_RY26_P04_V10_DY24_BGM.csv)

<a id="topic-4.1-19"></a>

### Redosing rates of on-demand agents reported in a new drug fact blast for a state Medicaid program

> “New Drug Fact Blast”

Source: [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx)

| Product | Redosing rates reported (share of episodes) |
| --- | --- |
| Sebetralstat (Ekterly) | “13%–38% of” |
| Icatibant (Firazyr, Sajazir) | “7%–44% of” |
| C1 esterase inhibitor, plasma-derived (Berinert) | “8%–30% of” |
| Ecallantide (Kalbitor) | “6%–18% of” |
| C1 esterase inhibitor, recombinant (Ruconest) | “2%–10% of episodes” |

Source: [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx)

<a id="topic-4.1-20"></a>

### On-demand drug cost per attack treated in the United States, 2018

> “Treatment for HAE is costly; medications for on-demand therapy range in cost from $5,000 to more than $12,000 per attack treated in the US, and treatment with medications for long-term prophylaxis may cost upwards of $500,000 annually.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-21"></a>

### On-demand drug cost inputs per dose in a published US prophylaxis model

> “All patients were assumed to have access to on-demand treatment for acute attacks in the comparator arm.”
> “For on-demand treatment, we computed the average costs per attack in each treatment setting as the cost of these drugs weighted by the proportion of attacks treated with each drug in each treatment setting.”
> “We assumed that equal proportions of attacks were treated with each drug in each treatment setting, noting that Kalbitor is not approved for home or self-administration.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

| Parameter | Berinert | Kalbitor | Firazyr | Ruconest |
| --- | --- | --- | --- | --- |
| Dose schedule | “20 IU/kg” | “30 mg” | “30 mg” | “50 IU/kg” |
| FSS per dose | “$4,174” | “$11,174” | “$7,178” | “$10,112” |
| ASP per dose | “$9,807” | “$15,594” | “$7,178” | “$15,164” |
| Percentage requiring extra dose | “1.9%” | “12.0%” | “12.7%” | “6.6%” |

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

> “Federal Supply Schedule or Big 4 price as of September 15, 2018.”
> “Average sales price as of June 13, 2018, plus 9% markup for administration in physicians’ office, home infusion, and hospital outpatient settings.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-22"></a>

### Health care utilization and productivity costs per attack in a published US prophylaxis model

> “Direct costs of acute attacks included drug costs, costs of a home nurse ($177), and physician office administration of on-demand treatment ($262) from Graham et al., 2017,94 and costs of ED visits ($1,479, 95% CI: $1,028-$1,929) and hospitalizations ($4,760, 95% CI: $3,612-$5,907) from Zilberberg et al.87,95”
> “Indirect costs (including missed work, child care, and travel) for acute attacks (by severity) were obtained from Wilson et al., 201099: $959 for mild, $4,048 for moderate, and $6,656 for severe attacks, after adjustment for the mean number of attacks (26.9).”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-23"></a>

### Cost per attack with icatibant and plasma-derived C1 inhibitor: Italian cohort

> “For the cost analysis of C1-INH-HAE attack, the perspective of the Italian National Health Service was taken.”
> “Of the total number of attacks, 1190 (78.9%) were treated with ODT, of which 704 with pdC1-INH (59.2% of treated attacks) and 486 with icatibant.”
> “The average cost for a single attack cost was €1183 (SD €789) including drug costs, emergency department visits and diagnostic tests.”
> “The unadjusted mean cost per attack was €1069 (SD €470) with pdC1-INH and €1651 (SD €469) with icatibant.”
> “After controlling for attack site and severity, the cost of treating an attack with icatibant was still 54% higher than pdC1-INH (figure 3).”

Source: [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/)

<a id="topic-4.1-24"></a>

### Direct and indirect costs of on-demand treatment alone: US patient survey

> “Per patient/year direct costs associated with modeled on-demand–only treatment totaled $363,795, with additional indirect socioeconomic costs of $52,576 per patient/year.”
> “Medications comprise the largest component (62.5%) of modeled on-demand–only treatment, at an estimated $227,674 per patient per year.”
> “The second highest component cost was hospitalization for treatment of an HAE attack (22.1%), followed by ED visits (12.5%).”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-4.1-25"></a>

### Annual healthcare cost components before and after starting long-term prophylaxis: US commercial claims

| Cost component, per patient per year | Pre-index | Post-index |
| --- | --- | --- |
| Medical costs, emergency room and inpatient | “$23,060” | “$14,716” |
| Medical costs, outpatient, home health, and other | “$2255” | “$1668” |
| Pharmacy costs, on-demand | “$217,857” | “$167,462” |
| Pharmacy costs, other | “$14,214” | “$4193” |
| Pharmacy costs, long-term prophylaxis | “$0” | “$395,845” |
| Total healthcare costs | “$165,348” | “$515,333” |

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

> “Among patients with at least 1 claim (ie, utilized healthcare services).”

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

<a id="topic-4.1-26"></a>

### Savings per attack from icatibant self-administration: Spanish cost-minimization model

> “Economic evaluation model based on the building of a decision tree. Both strategies are assumed to have equivalent effectiveness.”
> “The time horizon was one year.”
> “Since the model assumes that both strategies are equally effective [8,10,11], this is a cost-minimization study.”
> “From the social perspective, which considers both direct (health care costs) and indirect costs (productivity losses), strategy 2 would result into average savings of €121.30 per acute attack compared to strategy 1.”
> “For Spain, this would achieve in an annual savings of €551,371.”

Source: [Blasco et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3584739/)

<a id="topic-4.1-27"></a>

### Cost-effectiveness of on-demand recombinant and plasma-derived C1 inhibitor, icatibant, and ecallantide: US decision-tree model

> “To estimate the cost-effectiveness of on-demand treatment for HAE attacks, a decision-tree model from the U.S. commercial payer perspective was developed using TreeAge Pro 2018 R1 release”
> “Four on-demand HAE treatments were included: ecallantide, icatibant, plasma-derived (pd)C1-INH, and recombinant human (rh)C1-INH.”
> “All costs are dated to 2019, either directly or by inflation using the medical-care inflation subset of the Consumer Price Index for All Urban Consumers.”
> “The base case model outputs show costs and calculated effectiveness per attack at $12,905 and 0.806 for rhC1-INH, $14,806 and 0.765 for icatibant, $14,668 and 0.769 for pdC1-INH, and $21,068 and 0.792 for ecallantide, respectively.”
> “Cost per QALY was calculated using 26.9 attacks per person-year, leading to results of $420,941 for rhC1-INH, $488,349 for icatibant, $483,892 for pdC1-INH, and $689,773 for ecallantide.”
> “Results from this model indicate that rhC1-INH is the dominant treatment option with lower expected costs and higher calculated effectiveness than comparators.”

Source: [Bernstein et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391298/)

<a id="topic-4.1-28"></a>

### Cost-utility of conestat alfa and plasma-derived C1 esterase inhibitor versus placebo: Polish discrete event simulation

> “The cost-utility analysis from the Polish healthcare payer's perspective was performed for 1 year (2012).”
> “The incremental costs of each intervention compared with placebo were listed together (direct or indirect comparisons between options were impossible due to limited clinical data available).”
> “Discrete event simulation (DES) is one way of observing the time-dependent (or dynamic) behavior of a system”
> “Time horizon was set at one year, which seemed to be a reasonable compromise between the short clinical trials observation time and the median life expectancy horizon.”
> “In the base case analysis with a one year's perspective, patients with HAE suffering from life-threatening angioedema attacks gained on average 0.0261 quality adjusted life years (QALY) when treated with Ruconest® (conestat alfa) and 0.0262 QALY when treated with Berinert® P compared with placebo (Table 2).”
> “The incremental costs of the therapy of a single acute angioedema attack with conestat alfa amounted to app. EUR 419, app. EUR 755 per patient for human C1-INH treatment in comparison with placebo, thus indicating that conestat alfa is the cheapest option (Table 2).”
> “The median incremental cost-utility ratios for assessed interventions compared with placebo were as follows: EUR 15,226 per QALY (conestat alfa) and EUR 27,786 per QALY (human C1 esterase inhibitor)”
> “The cost-utility of the therapy was assumed when the ICUR was lower than EUR 24,279 (PLN 99,543) per QALY, which is set as threshold acceptability in Poland (tripled GDP per capita)”

Source: [Kawalec et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3834719/)

<a id="topic-4.1-29"></a>

### Utility weights with and without an acute attack used in a US on-demand model

> “Utility values were drawn from the literature”
> “citing a utility of 0.51 when experiencing attack symptoms and 0.83 without symptoms.”
> “Nonattack baseline utility and attack utility were implemented for effectiveness calculations; time to attack resolution was considered as well.”

Source: [Bernstein et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391298/)

<a id="topic-4.1-30"></a>

### Attack disutilities by severity used in a published US prophylaxis model

> “The estimated mean ± standard error EQ-5D today (i.e., “attack free”) utility score was 0.825 ± 0.207.”
> “The difference between the EQ-5D today and EQ-5D attack scores of the latest attack were 0.070 for mild, 0.369 for moderate, and 0.486 for severe attacks (Figure 2 in Nordenfelt et al., 2014).32”
> “We used these as the disutilities associated with mild, moderate, and severe attacks, respectively.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-31"></a>

### EQ-5D utility during and between attacks mapped from a European burden-of-illness survey

> “Survey items that overlapped conceptually with the EuroQol 5-Dimensions (EQ-5D) domains (pain/discomfort, mobility, self-care, usual activities, and anxiety/depression) were manually crosswalked to the corresponding UK population-based EQ-5D utility weights.”
> “Overall, a total of 111 HAE-BOIS-Europe participants completed all selected survey items and thus allowed for computation of EQ-5D-based utilities.”
> “The mean utilities for an HAE attack and between attacks were 0.44 and 0.72, respectively.”
> “Utilities for an acute attack were dependent on the severity of pain of the last attack (0.61 for no pain or mild pain, 0.47 for moderate pain, and 0.08 for severe pain).”

Source: [Aygören-Pürsün et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5019462/)

<a id="topic-4.1-32"></a>

### EQ-5D-5L index during treated attacks by time to on-demand treatment: US patient survey

> “Respondents were categorized into those who did (Treated Cohort) and did not (Untreated Cohort) manage their last attack with on-demand treatment (OD).”
> “In the Treated Cohort, the mean (SD) EQ-5D-5L index score was 0.849 (0.2) “Today” and 0.568 (0.3) “During the last treated attack” (Fig. 1A), with the latter score indicative of substantial impairment in HRQoL.”
> “The mean (SD) index score was 0.667 (0.3) in patients who treated <1 h of attack onset and 0.504 (0.3) in those who treated 5 to < 8 h of attack onset (Fig. 1B).”
> “In the Untreated Cohort, the mean (SD) EQ-5D-5L index score was 0.859 (0.2) “Today” and 0.661 (0.3) “During the last untreated attack” (Fig. 5).”
> “Funding for Outcomes Insights was provided by KalVista Pharmaceuticals (Cambridge, MA, USA).”

Source: [O'Connor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12320545/)

<a id="topic-4.1-33"></a>

### Time trade-off utilities by attack location and for caregivers: general public in England

> “Members of the general public in England rated vignettes in TTO interviews, which included a visual analogue scale (VAS) component.”
> “The TTO values were as follows: attack-free, 0.783 (standard deviation [SD] 0.316); hand: 0.582 (SD 0.380); facial: 0.483 (SD 0.448); abdominal: 0.345 (SD 0.458); and laryngeal: 0.128 (SD 0.529).”
> “The caregiver rating was 0.762 (SD 0.303).”
> “This study was funded by BioCryst Pharmaceuticals, Inc.”

Source: [Lo et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8864034/)

<a id="topic-4.1-34"></a>

### Patient-defined attack severity for future economic evaluations: US qualitative study

> “This study aimed to explore how adults with HAE define attack severity, including the role of attack location and attack phase, to inform the characterization of attack severity in cost-effectiveness evaluations.”
> “Semi-structured qualitative interviews were conducted with US adults with HAE, purposively sampled with quotas for attack severity and attack locations.”
> “A total of 25 adults with HAE took part in the interviews.”
> “Overall, patient-defined severity, shaped by location, phase, and context, challenges simple severity classifications and indicates that severity definitions should also incorporate attack location, symptoms and phase to more accurately evaluate the benefit of new treatments.”

Source: [Gallop et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2740956)

<a id="topic-4.1-35"></a>

### Health technology assessment of oral on-demand sebetralstat, England: draft recommendation and price

> “Sebetralstat should not be used to treat hereditary angioedema attacks in people 12 years and over.”
> “Usual treatment of acute hereditary angioedema attacks in people 12 years and over includes icatibant or a C1-esterase inhibitor (C1-INH) such as Berinert, Cinryze or Ruconest.”
> “Because of the uncertainties in the clinical evidence and economic model, it is not possible to determine the most likely cost-effectiveness estimates for sebetralstat.”
> “The list price of sebetralstat is £12,000 for a 300-mg pack of 6 tablets (including VAT, company submission).”
> “The company has a commercial arrangement, which would have applied if sebetralstat had been recommended.”

Source: [NICE sebetralstat draft guidance (2025)](https://www.nice.org.uk/guidance/gid-ta11334/documents/draft-guidance)

<a id="topic-4.1-36"></a>

### Health technology assessment of oral on-demand sebetralstat, England: comparators, additional dosing, and utility inputs

> “The committee agreed with the EAG and concluded that a fully incremental analysis was the most appropriate approach based on the evidence presented.”
> “The committee noted the rate of additional dosing for sebetralstat (22.25%), sourced from the KONFIDENT-S open-label extension study, was higher than for icatibant (8.91%), Cinryze and Ruconest (18.18%), and Berinert (1.11%).”
> “KONFIDENT did not collect health-related quality of life data.”
> “This was informed by a time trade-off analysis by Lo et al. (2022).”
> “The company base case did not apply a disutility difference between subcutaneous and oral administration, because the result was not statistically significant.”
> “It provided a scenario with the utility difference applied which resulted in a large reduction in the ICER.”

Source: [NICE sebetralstat draft guidance (2025)](https://www.nice.org.uk/guidance/gid-ta11334/documents/draft-guidance)

<a id="topic-4.1-37"></a>

### Health technology assessment of oral on-demand sebetralstat, England: cost-effectiveness estimates

> “The exact ICERs are confidential and cannot be reported here because they include confidential discounts for sebetralstat and C1-INHs.”
> “The company base-case ICER comparing sebetralstat with a basket of treatments was considerably higher than £30,000 per QALY gained.”
> “The EAG base-case ICER comparing sebetralstat with icatibant was considerably higher than the company base-case results”
> “The committee noted that the EAG-preferred assumptions using the eMIT price for icatibant and a fully incremental analysis had a substantial impact on the ICER.”

Source: [NICE sebetralstat draft guidance (2025)](https://www.nice.org.uk/guidance/gid-ta11334/documents/draft-guidance)

<a id="topic-4.1-38"></a>

### Status of the English appraisal of sebetralstat, November 2026

> “Following the second committee meeting for sebetralstat, NICE paused publication of the draft guidance due to exceptional circumstances.”
> “An updated commercial offer has now been agreed.”
> “NICE has agreed to a short pause to publication of the final draft guidance until mid-November to support continued patient access while these arrangements are finalised.”
> “Sebetralstat remains available through the Early Access to Medicines Scheme (EAMS) plus route during this period.”

Source: [NICE sebetralstat project page (2026)](https://www.nice.org.uk/guidance/indevelopment/gid-ta11334)

<a id="topic-4.1-39"></a>

### Health technology assessment of oral on-demand sebetralstat, Germany: added benefit and treatment costs

> “Hint for a non-quantifiable additional benefit since the scientific data does not allow quantification.”
> “No data were collected in the category of health-related quality of life.”
> “For the treatment duration within a year, the treatment of just one attack every three weeks is taken into account as the lower limit, and one attack every week as the upper limit.”
> “With regard to consumption, the administration of 1 or 2 doses per attack is therefore taken into account.”

Source: [G-BA sebetralstat resolution justification (2026)](https://www.g-ba.de/downloads/40-1465-12519/2026-04-02_AM-RL-XII_Sebetralstat_D-1248_TrG_EN.pdf)

| Therapy | Packaging size | Costs (pharmacy sales price) | Costs after deduction of statutory rebates |
| --- | --- | --- | --- |
| “Sebetralstat” | “6 FCT” | “€ 17,707.74” | “€ 16,697.97” |

Source: [G-BA sebetralstat resolution justification (2026)](https://www.g-ba.de/downloads/40-1465-12519/2026-04-02_AM-RL-XII_Sebetralstat_D-1248_TrG_EN.pdf)

<a id="topic-4.1-40"></a>

### Health technology assessment of oral on-demand sebetralstat, France: clinical benefit, added benefit, and target population

> “Adopté par la Commission de la transparence le 22 avril 2026”
> “la Commission considère que EKTERLY 300 mg (sébétralstat), comprimé enrobé, n’apporte pas d’amélioration du service médical rendu (ASMR V) dans la stratégie thérapeutique actuelle qui comprend les comparateurs pertinents cités dans le paragraphe 2.2.”
> “la Commission considère que le service médical rendu par EKTERLY 300 mg (sébétralstat), comprimé enrobé, est important dans l’indication de l’AMM.”
> “Le nombre de patients atteints d’AOH serait donc au total de l’ordre de 1 850 patients en France.”
> “La population cible est estimée à 1 600 patients.”

Source: [HAS EKTERLY transparency committee opinion (2026)](https://www.has-sante.fr/upload/docs/evamed/CT-21620_EKTERLY_PIC_INS_AvisDef_CT21620.pdf)

<a id="topic-4.1-41"></a>

### Quantity limits for oral sebetralstat: national commercial formulary

> “REVIEW DATE: 07/08/2026”
> “CIGNA NATIONAL FORMULARY COVERAGE:”
> “The second rescue dose was given for 39.8% of Ekterly-treated attacks.”
> “The quantity limits outlined below provide for the patient to treat 4 attacks (at the maximum Ekterly dose) per 28 days, with an override provided to treat an additional 4 attacks (at the maximum Ekterly dose) each month.”
> “This is a quantity sufficient to treat four acute hereditary angioedema attacks in each 28-day period, assuming that the patient requires two 600 mg doses in a 24-hour period to treat the attack.”

Source: [Cigna Ekterly drug quantity management policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_934_coveragepositioncriteria_hae_ekterly_dqm_per_days.pdf)

<a id="topic-4.1-42"></a>

### Step therapy through generic icatibant and quantity limits for on-demand agents: regional health plan policy

> “For patients 18 years of age and older, requests for Ekterly will require documentation of therapeutic failure, severe intolerance, OR a contraindication to generic icatibant.”
> “Quantity limit of 4 tablets per 30 days.”
> “Both initial and recertification/continuation of therapy requests for brand Firazyr will require documentation of therapeutic failure, severe intolerance, or a contraindication to a trial with generic Icatibant.”
> “Quantity limit of #3 (3ml each) pre-filled syringes – 9ml/30 days.”
> “Quantity limit of 10 vials per 30 days on Rx benefit”
> “Individuals will only be authorized for one acute HAE medication at one time.”

Source: [Univera Healthcare hereditary angioedema pharmacy policy (2026)](https://www.univerahealthcare.com/documents/d/global/hereditary-angioedema-hae-pdf)

<a id="topic-4.1-43"></a>

### Step therapy through generic icatibant and C1 inhibitor, and acute-treatment quantity limits: regional health plan policy

> “Effective Date: April 1, 2026”
> “Clinical documentation (such as chart notes) confirming that treatment with the following has been ineffective, not tolerated, or contraindicated:”
> “Generic icatibant.”
> “Berinert (plasma-derived C1-INH)”
> “Ruconest (recombinant C1-INH)”
> “Acute treatments for HAE may be authorized in a quantity sufficient for the treatment of three attacks per month.”
> “Generic icatibant is the lowest cost of all available options.”

Source: [Regence medication policy dru535 (2026)](https://regence.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/Cambia/Program_Summaries/dru535reg.pdf)

<a id="topic-4.1-44"></a>

### Preferred product for on-demand agents under a health plan medical benefit

> “guideline is specific to the Health Plan’s medical benefit.”
> “Berinert [c-1 esterase inhibitor (human), J0597]”
> “Firazyr (icatibant, J1744)”
> “Kalbitor (ecallantide, J1290)”
> “Ruconest [c-1 esterase inhibitor (recombinant), J0596]”
> “For non-preferred requests: Must have a trial and failure or intolerance of the preferred product or have a contraindication to the preferred product”

Source: [CountyCare acute HAE products guideline (2026)](https://countycare.com/wp-content/uploads/ECG_5000.CC-for-Acute-Hereditary-Angioedema-Products-ver-Jan-26.pdf)

<a id="topic-4.1-45"></a>

### State Medicaid prior authorization criteria for oral sebetralstat

> “Prior Authorization Approval Criteria”
> “Medication will be used for on-demand treatment of acute HAE attacks”
> “Initial approval period: 6 months”

Source: [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx)

<a id="topic-4.1-46"></a>

### Deucrictibant in a state Medicaid pipeline listing, December 2025

> “Implication to State Medicaid Program”
> “Deucrictibant”
> “Phase III trial (NCT06669754)”
> “Estimated completion: August 2026”

Source: [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx)

<a id="topic-4.1-47"></a>

### US diagnosed prevalence from claims data

> “For 2018, 2019, and 2020, the claims-based algorithm yielded overall annual unadjusted HAE prevalence estimates per 100,000 and number of people diagnosed with HAE of 2.67, 9559; 2.61, 9341; and 2.43, 8694, respectively.”
> “The corresponding estimates based on expert physician analysis were 2.13, 7602; 2.03, 7275; and 1.84, 6595, respectively.”

Source: [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/)

<a id="topic-4.1-48"></a>

### US population with C1 inhibitor deficiency and on-demand-only treatment in a patient survey

> “Hereditary angioedema (HAE) caused by C1 inhibitor (C1-INH) deficiency is a rare, debilitating, and potentially fatal genetic disorder that affects <8000 people in the United States.”
> “Of the 737 patients included in the final analysis, 37.3% (n = 275) were prescribed and using on-demand–only treatment and reported treating 67.2% of their HAE attacks.”
> “Of the 62.7% (n = 462) who received prophylactic treatment in addition to having on-demand treatment available, 32.3% (n = 149) received one of the novel SC prophylactic therapies (C1-INH [SC] or lanadelumab).”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-4.1-49"></a>

### Share of US patients treated with long-term prophylaxis and on-demand use during prophylaxis

> “In the United States, approximately 70% of patients with HAE are treated with LTP, primarily non-androgens.”
> “Most patients (67%) had ≥1 post-index on-demand therapy claim.”

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

<a id="topic-4.1-50"></a>

### Company statement on hereditary angioedema market size

> “Global sales of treatments for HAE in 2024 were estimated at approximately $2.7 billion based on publicly available information and, according to public research reports, are forecast to grow at an approximately 5% compound annual growth rate to $4.7 billion through 2036.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-4.1-51"></a>

### Market size estimate in another hereditary angioedema developer's prospectus

> “The HAE market, including acute and prophylactic treatments, was approximately $3.12 billion in 2024 and is estimated to reach approximately $6.83 billion in global sales by 2032 according to forecasts from Evaluate Pharma (June 9, 2026), with prophylactic treatment representing a significant majority.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-4.1-52"></a>

### Company statement on disease frequency and the US patient population

> “According to scientific publications, patients experience a median of 14 attacks per year, and half of patients experience a potentially life-threatening airway attack at least once in their lifetime.”
> “According to HAE International, as of October 2014, HAE affected from 1:30,000 to 1:80,000 individuals globally, or at least 7,000 patients in the U.S. and at least 15,000 patients in the EU.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-4.1-53"></a>

### Company statement on pricing relative to generic products

> “If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic products.”
> “Generic products are expected to become available over the coming years, potentially creating pricing pressure.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-4.1-54"></a>

### Company statement on the on-demand market and intended position of deucrictibant

> “The mechanism of action of the most widely used on-demand HAE treatment is inhibition of the bradykinin B2 receptor; other mechanisms include replacement of C1INH or inhibition of plasma kallikrein.”
> “An oral on-demand treatment could decrease the burden of therapy by improving convenience through easier administration, portability, and discretion.”
> “With the encouraging RAPIDe-3 results, combined with the trusted bradykinin B2 receptor antagonist mechanism seen in both icatibant and deucrictibant, we believe deucrictibant could become standard of care for on-demand treatment.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-4.1-55"></a>

### Company statements on launch preparation, pricing research, and expected revenue, third quarter 2026

> “expenses related to the build-out of our commercial organization, including hiring of personnel, assessments of the HAE market landscape, pricing research, and congress attendance.”
> “The increase in general and administrative expenses is primarily due to increases in commercial personnel, professional, and other expenses, supporting a potential launch of IR in 2027.”
> “The increase is primarily due to HAE market data expenses supporting the potential launch of IR in 2027.”
> “We expect to recognize revenues from sales in 2027, if deucrictibant IR is approved for sale by the FDA then.”

Source: [Pharvaris Form 6-K, third quarter 2026 MD&A (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
